Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

17.49
-1.1000-5.92%
Post-market: 17.600.1100+0.63%19:38 EDT
Volume:1.90M
Turnover:34.23M
Market Cap:2.99B
PE:-6.41
High:19.06
Open:18.77
Low:17.39
Close:18.59
Loading ...

Jay S. Stout, Chief Technology Officer of Immunovant Inc., Reports Disposal of Common Shares

Reuters
·
12 Jul

Goldman Sachs Resumes Coverage with a Hold Rating on Immunovant (IMVT)

TIPRANKS
·
10 Jul

Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease

TIPRANKS
·
26 Jun

Law Firm Launches Investigation into Immunovant Inc. Over Alleged Fiduciary Breaches in Private Placement Deal

Reuters
·
21 Jun

Immunovant Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
30 May

Guggenheim Reaffirms Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
30 May

Immunovant price target lowered to $35 from $51 at H.C. Wainwright

TIPRANKS
·
30 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Immunovant (IMVT) and Roivant Sciences (ROIV)

TIPRANKS
·
30 May

Immunovant's Fiscal Q4 Net Loss Widens

MT Newswires Live
·
29 May

Immunovant reports Q4 EPS (64c), consensus (72c)

TIPRANKS
·
29 May

Immunovant Q4 EPS $(0.64) Beats $(0.73) Estimate

Benzinga
·
29 May

BRIEF-Immunovant Q4 Net Income USD -106.449 Million

Reuters
·
29 May

Immunovant - Current Cash Balance Provides Runway for Announced Indications Through GD Readout Expected in 2027

THOMSON REUTERS
·
29 May

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

THOMSON REUTERS
·
29 May

Immunovant Q4 Basic EPS USD -0.64

THOMSON REUTERS
·
29 May

Immunovant Q4 Net Income USD -106.449 Million

THOMSON REUTERS
·
29 May

Immunovant: Expects to Report Batoclimab 6-Month Remission Data From Proof-of-Concept Study in GD in Summer of 2025

THOMSON REUTERS
·
29 May

Immunovant: Expects to Report Phase 3 Thyroid Eye Disease (Ted) Data in H2 of Cy2025

THOMSON REUTERS
·
29 May

Press Release: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Dow Jones
·
29 May

Immunovant Inc expected to post a loss of 72 cents a share - Earnings Preview

Reuters
·
28 May